3-Homotetrahydrocannibinol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581471

CAS#: 117-51-1

Description: 3-Homotetrahydrocannibinol, euphoric for treatment of thalamus disorders.


Chemical Structure

img
3-Homotetrahydrocannibinol
CAS# 117-51-1

Theoretical Analysis

MedKoo Cat#: 581471
Name: 3-Homotetrahydrocannibinol
CAS#: 117-51-1
Chemical Formula: C22H32O2
Exact Mass: 328.2402
Molecular Weight: 328.496
Elemental Analysis: C, 80.44; H, 9.82; O, 9.74

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: 3-Homotetrahydrocannibinol; Parahexyl; Synhexyl; Pyrahexyl

IUPAC/Chemical Name: 3-Hexyl-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol

InChi Key: OORFXDSWECAQLI-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H32O2/c1-5-6-7-8-9-16-13-19(23)21-17-12-15(2)10-11-18(17)22(3,4)24-20(21)14-16/h13-15,23H,5-12H2,1-4H3

SMILES Code: OC1=C(C2=C(CCC(C)C2)C(C)(C)O3)C3=CC(CCCCCC)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 328.496 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fairchild MD, Jenden DJ, Mickey MR, Yale C. EEG effects of hallucinogens and cannabinoids using sleep-waking behavior as baseline. Pharmacol Biochem Behav. 1980 Jan;12(1):99-105. PubMed PMID: 6102770.

2: Bailey K. The value of the Duquénois test for cannabis--a survey. J Forensic Sci. 1979 Oct;24(4):817-41. PubMed PMID: 232123.

3: Ono M, Shimamine M, Takahashi K, Inoue T. [Studies on hallucinogens. VII Synthesis of parahexyl]. Eisei Shikenjo Hokoku. 1974;49(92):46-50. Japanese. PubMed PMID: 4477495.

4: Hollister LE, Moore F, Kanter S, Noble E. 1 -tetrahydrocannabinol, synhexyl and marijuana extract administered orally in man: catecholamine excretion, plasma cortisol levels and platelet serotonin content. Psychopharmacologia. 1970;17(4):354-60. PubMed PMID: 5523370.

5: Hollister LE. Steroids and moods: correlations in schizophrenics and subjects treated with lysergic acid diethylamide (LSD), mescaline, tetrahydrocannabinol, and synhexyl. J Clin Pharmacol J New Drugs. 1969 Jan-Feb;9(1):24-9. PubMed PMID: 5250309.

6: Hollister LE, Richards RK, Gillespie HK. Comparison of tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther. 1968 Nov-Dec;9(6):783-91. PubMed PMID: 5721981.

7: HILL HE, HAERTZEN CA, WOLBACH AB Jr, MINER EJ. THE ADDICTION RESEARCH CENTER INVENTORY: STANDARDIZATION OF SCALES WHICH EVALUATE SUBJECTIVE EFFECTS OF MORPHINE, AMPHETAMINE, PENTOBARBITAL, ALCOHOL, LSD-25, PYRAHEXYL AND CHLORPROMAZINE. Psychopharmacologia. 1963 May 15;4:167-83. PubMed PMID: 14048539.

8: THOMPSON LJ, PROCTOR RC. The use of pyrahexyl in the treatment of alcoholic and drug withdrawal conditions. N C Med J. 1953 Oct;14(10):520-3. PubMed PMID: 13099650.

9: POND DA. Psychological effects in depressive patients of the marihuana homologue synhexyl. J Neurol Neurosurg Psychiatry. 1948 Nov;11(4):271-9. PubMed PMID: 18894648; PubMed Central PMCID: PMC498372.

10: WILLIAMS EG, HIMMELSBACH CK, et al. Studies on marihuana and pyrahexyl compound. Public Health Rep. 1946 Jul 19;61:1059-83. PubMed PMID: 20992145.